Condition

Cardiac Iron Overload (2)

Transfusion-dependent β-thalassemia Patients (1)

Overall Status

Completed (1)

Terminated (1)

Sign in for free

Phase

phase 2 (2)

Sponsor

Novartis Pharmaceuticals (2)

Collaborator

Intervention

deferasirox (1)

deferasirox and deferoxamine (1)

deferoxamine (dfo) (1)

Study Documents

Intervention Type

drug (2)

Funder Type

Industry (2)

Study Type

Interventional (2)

cardiac iron overload

Showing 1 - 2 of 2

Trials per page:

STUDY

CONDITIONS

INTERVENTIONS

LOCATIONS

Cardiac Iron Overload Trial in Worldwide (Deferasirox and Deferoxamine)

Completed

Cardiac Iron Overload

Deferasirox and Deferoxamine

Toronto, Ontario, Canada
+14 more

Jul 23, 2021

Transfusion-dependent ß-thalassemia Patients, Cardiac Iron Overload Trial in Athens, Patras (Deferasirox, Deferoxamine (DFO))

Terminated

Transfusion-dependent β-thalassemia Patients
Cardiac Iron Overload

Deferasirox
Deferoxamine (DFO)

Athens, GR, Greece
+3 more

Oct 21, 2019